SSGJ-707
Phase 3Small molecule
SSGJ-707 is one of 153 small molecule programs targeting Metastatic Colorectal Cancer. It is currently in Phase 3.
5
Indications
5
Total Trials
5
Active Trials
152
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
414 competitors in Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1Trodelvy
GileadPhase 3
SSGJ-707
SSunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Phase 3
TGRX-326
SShenzhen TargetRx Co., Ltd.
Phase 3
HD204
PPrestige Biopharma Limited
Phase 3
Remeron
OOrganon and Co
Preclinical
Aqupla
Jiangsu Simcere Pharmaceutical Co., Ltd.Preclinical
Ftorafur
TThe First Affiliated Hospital with Nanjing Medical University
Preclinical
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Treatment
GSKPreclinical
PD-1 Inhibitors
BBioNTech US Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Metastatic Colorectal Cancer1 trial
Combination Therapy1 trial
Advanced NSCLC1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SSGJ-707. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details